Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb14045 · 1 trial · 4 indications
Treatment-related adverse events as assessed by CTCAE v4.03
| Arm | Type | Description |
|---|---|---|
| XmAb14045 | EXPERIMENTAL | Biological/Vaccine: XmAb14045 Administered IV weekly up to 8 weeks |
| Name | Type | Description |
|---|---|---|
| XmAb14045 | BIOLOGICAL | Administered IV weekly up to 8 weeks, with or without step-up dosing |
Inclusion Criteria: * Diagnosis of 1 of the following diseases: * Primary or secondary AML (including erythroleukemia and eosinophilic leukemia, but excluding acute promyelocytic leukemia) * B-cell ALL * BPDCN * CML in blast phase, resistant or intolerant to tyrosine kinase inhibitor thera...
XmAb14045 is an investigational monoclonal antibody being studied for the treatment of Acute Myelogenous Leukemia (AML). It was evaluated in a Phase 1 clinical trial in patients with CD123-expressing hematologic malignancies, including AML, B-cell acute lymphoblastic leukemia, blastic plasmacytoid dendritic cell neoplasm, and chronic myeloid leukemia in blast crisis.
XmAb14045 is being developed by Xencor, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol XNCR. The company sponsored the Phase 1 clinical trial of this investigational antibody for hematologic malignancies.
XmAb14045 is in Phase 1 clinical development. The single Phase 1 study evaluating this investigational drug has been completed. It is not approved by the FDA and remains an investigational agent in clinical development for Acute Myelogenous Leukemia and other CD123-expressing hematologic malignancies.
XmAb14045 was studied in one clinical trial, registered as NCT02730312. This was a Phase 1 study to evaluate the safety and tolerability of XmAb14045 in patients with CD123-expressing hematologic malignancies. The trial enrolled 120 participants in the United States and has been completed.
XmAb14045 targets CD123, a protein expressed on the surface of certain hematologic malignancies. The Phase 1 trial enrolled patients with CD123-expressing cancers, including Acute Myelogenous Leukemia, B-cell acute lymphoblastic leukemia, blastic plasmacytoid dendritic cell neoplasm, and chronic myeloid leukemia in blast crisis.